Skip to main content Help with accessibility Skip to main navigation

Position Statements

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 16 - June - 2023
BNF chapter: Respiratory system

LSCMMG has granted interim approval for this position statement ONLY. LSCMMG is aware that each locality, prior to the establishment of the ICB, had adopted the 'Over the counter items that should not be routinely prescribed in primary care policy'.

Interim approval has been granted to provide consistency of advice to prescribers whilst the ICB considers whether to adopt the 'Over the counter items that should not be routinely prescribed in primary care policy' across Lancashire and South Cumbria. 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - June - 2015
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 12 - September - 2019
BNF chapter: Skin

Medical camouflaging products must only be initiated by a healthcare professional that specialises in skin colour matching and appropriate application techniques.
Please note: these products must only be continued in primary care if the patient’s GP believes issuing such a prescription will continue to significantly reduce the impact of the patient’s medical condition.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - January - 2019
BNF chapter: Central nervous system

This guidance does not apply to the use of Sativex® (delta-9-etrahydrocannabinol and cannabidiol) oromucosal spray as an adjunct treatment for moderate to severe spasticity in multiple sclerosis

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 19 - July - 2022
BNF chapter: Central nervous system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - February - 2018

Denosumab as a second-line treatment option for the prevention of Osteoporotic Fragility Fractures

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2016
BNF chapter: Central nervous system

The Lancashire Medicines Management Group does not recommend the prescribing of e-Cigarettes

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 16 - November - 2022

Where a proprietary biological medicine is indicated and biologically similar (biosimilar) medicine(s) to the reference product also exist the product with the lowest acquisition price should be used and charged to the commissioning organisation at the acquisition price (within licensed indications).

Product choices, including changes to treatment, for individual patients should be made following assessment by the responsible clinician taking into account patient choice.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 16 - June - 2023

LSCMMG has granted interim approval for this position statement ONLY. LSCMMG is aware that each locality, prior to the establishment of the ICB, had adopted the 'Over the counter items that should not be routinely prescribed in primary care policy'.

Interim approval has been granted to provide consistency of advice to prescribers whilst the ICB considers whether to adopt the 'Over the counter items that should not be routinely prescribed in primary care policy' across Lancashire and South Cumbria. 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 14 - September - 2022
BNF chapter: Central nervous system

To be read in conjunction with the LSCMMG guideline ‘Assessing suitability of strong opioid use’

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 11 - January - 2024
BNF chapter: Blood and Nutrition
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 20 - January - 2022
BNF chapter: Cardiovascular system

Please refer to the LSCMMG inclisiran medicines entry for further information on use within Lancashire and South Cumbria - RAG rated 'Green (Restricted)'.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 03 - July - 2023
BNF chapter: Central nervous system

Please note: a standard operating procedure for switching Keppra preparations to generic levetiracetam preparations is available in support of the position statement below. This is for use by practice supporting pharmacy teams across Lancashire and South Cumbria ICB ONLY

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 14 - November - 2022
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - February - 2018

Prescribing request from out-of-area specialists to Lancashire GPs where there is an inconsistency with the recommended local and out-of-area colour classification

**This Guideline is currently under review. For further information please click here**
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - July - 2018
BNF chapter: Blood and Nutrition
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Pending
Pending
Date Posted: 19 - March - 2021
BNF chapter: Endocrine system

Please note: GPs and other primary care prescribers are under no obligation to act upon the advice issued by a private specialist. If the NHS prescriber receiving the request does not believe they have the competence to initiate or continue the recommended intervention a referral to an appropriate NHS specialist should be made. Patients are entitled to receive additional private care if this is provided separately from NHS care.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 13 - February - 2024
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Not adopted
Date Posted: 01 - September - 2016
BNF chapter: Central nervous system

This position statement relates to the use of tapentadol MR for the following indications:

1. As a treatment option for intractable neuropathic pain in non-palliative care patients
2. As a treatment for nonspecific pain

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - April - 2016

Trans-anal Irrigation Systems are recommended for use within the Lancashire Health Economy for the treatment of Neurogenic Bowel Dysfunction and Non-Neurogenic Bowel Dysfunction including; chronic constipation and chronic faecal incontinence